-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, many listed pharmaceutical companies have released dividend plans that the industry is concerned about while disclosing their annual reports
.
Among them, many pharmaceutical companies including Yiqiao Shenzhou, Yunnan Baiyao, Livzon Group, Huitai Medical and other pharmaceutical companies distributed cash dividends exceeding 10 yuan per 10 shares
.
Yiqiao Shenzhou is proud to "distribute money".
According to the announcement on the implementation of the 2021 annual equity distribution issued by the company on March 23, the company will distribute a cash dividend of 100 yuan (including tax, after tax) for every 10 shares.
The total amount of cash dividends distributed is 680 million yuan
.
At the same time, 9 shares for every 10 shares were transferred to all shareholders with the capital reserve
.
According to the data, Yiqiao Shenzhou is a biotechnology company engaged in the research and development, production, sales and provision of technical services of biological reagents
.
The 2021 annual report shows that the company achieved a total operating income of 965 million yuan, a year-on-year decrease of 39.
53%; net profit attributable to shareholders of the parent company was 720 million yuan, a year-on-year decrease of 36.
15%; basic earnings per share was 12.
7061 yuan
.
It can be seen that although the company's performance has declined, the dividend plan is still relatively bold
.
And Yunnan Baiyao, which also has a net profit decline, plans to distribute cash dividends of 16.
00 yuan (tax included) to all shareholders for every 10 shares and 4 bonus shares (tax included)
.
In 2021, Yunnan Baiyao achieved a net profit of 2.
804 billion yuan, a year-on-year decrease of 49.
17%.
It is reported that this is the first time that Yunnan Baiyao has experienced a decline in annual net profit in the past 20 years
.
Compared with the cash dividends distributed per 10 shares in previous years, Yunnan Baiyao's dividends have also decreased
.
From 2018 to 2020, the company will distribute cash dividends of 20 yuan, 30 yuan, and 39 yuan for every 10 shares, without bonus shares
.
The main business of Yunnan Baiyao includes the research and development, production and sales of self-made industrial products, as well as pharmaceutical wholesale and retail business
.
Statistics show that Yunnan Baiyao is keen on investment.
In 2020, Yunnan Baiyao will hold many stocks such as Xiaomi Group, Yili, Hengrui Medicine, Kweichow Moutai, Tencent Holdings, etc.
, which also bring good income to the company
.
However, in the second half of 2021, the market has changed, and Yunnan Baiyao has reduced its positions.
While selling most of the stocks, it bought 3 Hong Kong stocks, but the gains were minimal
.
Livzon Group recently released a performance announcement.
In 2021, the operating income was 12.
064 billion yuan, a year-on-year increase of 14.
67%; the net profit attributable to shareholders of the listed company was 1.
776 billion yuan, a year-on-year increase of 3.
54%; basic earnings per share were 1.
90 yuan
.
It is reported that during the reporting period, the sales growth of the chemical preparations segment of the group was obvious, and the sales in key advantageous areas such as digestive tract, gonadotropins, and spirits achieved sustained and rapid growth year-on-year.
Steady growth of the company's overall performance
.
At the same time as the announcement of the annual report, the company also announced the profit distribution plan for 2021: it plans to distribute a cash dividend of RMB 13.
00 (tax included) for every 10 shares of the company to all shareholders of the company
.
In addition, Huitai Medical's 2021 distribution plan is: a cash dividend of RMB 10 (tax included) for every 10 shares, no conversion to increase, no bonus shares
.
The company's 2021 annual report shows that the realized revenue is 829 million yuan, a year-on-year increase of 72.
85%; the net profit attributable to shareholders of the listed company is 208 million yuan, a year-on-year increase of 87.
70%; the basic earnings per share is 3.
19 yuan per share
.
The performance growth is mainly due to the continuous expansion of the company's scale, and each product line has increased to varying degrees compared with the same period of the previous year.
Among them, the coronary access category has increased by 96.
77% compared with the same period of the previous year, and the peripheral intervention category has increased by 80.
95% compared with the same period of the previous year. .
The company is a company specializing in the field of electrophysiology and vascular interventional access consumables
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, many pharmaceutical companies including Yiqiao Shenzhou, Yunnan Baiyao, Livzon Group, Huitai Medical and other pharmaceutical companies distributed cash dividends exceeding 10 yuan per 10 shares
.
Yiqiao Shenzhou is proud to "distribute money".
According to the announcement on the implementation of the 2021 annual equity distribution issued by the company on March 23, the company will distribute a cash dividend of 100 yuan (including tax, after tax) for every 10 shares.
The total amount of cash dividends distributed is 680 million yuan
.
At the same time, 9 shares for every 10 shares were transferred to all shareholders with the capital reserve
.
According to the data, Yiqiao Shenzhou is a biotechnology company engaged in the research and development, production, sales and provision of technical services of biological reagents
.
The 2021 annual report shows that the company achieved a total operating income of 965 million yuan, a year-on-year decrease of 39.
53%; net profit attributable to shareholders of the parent company was 720 million yuan, a year-on-year decrease of 36.
15%; basic earnings per share was 12.
7061 yuan
.
It can be seen that although the company's performance has declined, the dividend plan is still relatively bold
.
And Yunnan Baiyao, which also has a net profit decline, plans to distribute cash dividends of 16.
00 yuan (tax included) to all shareholders for every 10 shares and 4 bonus shares (tax included)
.
In 2021, Yunnan Baiyao achieved a net profit of 2.
804 billion yuan, a year-on-year decrease of 49.
17%.
It is reported that this is the first time that Yunnan Baiyao has experienced a decline in annual net profit in the past 20 years
.
Compared with the cash dividends distributed per 10 shares in previous years, Yunnan Baiyao's dividends have also decreased
.
From 2018 to 2020, the company will distribute cash dividends of 20 yuan, 30 yuan, and 39 yuan for every 10 shares, without bonus shares
.
The main business of Yunnan Baiyao includes the research and development, production and sales of self-made industrial products, as well as pharmaceutical wholesale and retail business
.
Statistics show that Yunnan Baiyao is keen on investment.
In 2020, Yunnan Baiyao will hold many stocks such as Xiaomi Group, Yili, Hengrui Medicine, Kweichow Moutai, Tencent Holdings, etc.
, which also bring good income to the company
.
However, in the second half of 2021, the market has changed, and Yunnan Baiyao has reduced its positions.
While selling most of the stocks, it bought 3 Hong Kong stocks, but the gains were minimal
.
Livzon Group recently released a performance announcement.
In 2021, the operating income was 12.
064 billion yuan, a year-on-year increase of 14.
67%; the net profit attributable to shareholders of the listed company was 1.
776 billion yuan, a year-on-year increase of 3.
54%; basic earnings per share were 1.
90 yuan
.
It is reported that during the reporting period, the sales growth of the chemical preparations segment of the group was obvious, and the sales in key advantageous areas such as digestive tract, gonadotropins, and spirits achieved sustained and rapid growth year-on-year.
Steady growth of the company's overall performance
.
At the same time as the announcement of the annual report, the company also announced the profit distribution plan for 2021: it plans to distribute a cash dividend of RMB 13.
00 (tax included) for every 10 shares of the company to all shareholders of the company
.
In addition, Huitai Medical's 2021 distribution plan is: a cash dividend of RMB 10 (tax included) for every 10 shares, no conversion to increase, no bonus shares
.
The company's 2021 annual report shows that the realized revenue is 829 million yuan, a year-on-year increase of 72.
85%; the net profit attributable to shareholders of the listed company is 208 million yuan, a year-on-year increase of 87.
70%; the basic earnings per share is 3.
19 yuan per share
.
The performance growth is mainly due to the continuous expansion of the company's scale, and each product line has increased to varying degrees compared with the same period of the previous year.
Among them, the coronary access category has increased by 96.
77% compared with the same period of the previous year, and the peripheral intervention category has increased by 80.
95% compared with the same period of the previous year. .
The company is a company specializing in the field of electrophysiology and vascular interventional access consumables
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
